Does Diethylstilbestrol (DES) Cause SGPT (ALT) Elevation?
There is no evidence that diethylstilbestrol (DES) causes elevation of serum SGPT (ALT) levels. The available FDA drug labeling and medical literature do not identify hepatotoxicity or liver enzyme elevation as a known adverse effect of DES.
Evidence Review
FDA Drug Label
The FDA labeling for diethylstilbestrol 1 does not list hepatotoxicity, liver enzyme elevation, or ALT/SGPT elevation among its adverse effects or warnings. This is significant because drug-induced liver injury (DILI) serious enough to warrant clinical attention would be documented in official prescribing information.
Clinical Literature
A comprehensive review of DES health risks 2 identifies the major long-term complications associated with DES exposure:
- Increased breast cancer risk
- Cervical and vaginal clear cell adenocarcinoma
- Reproductive tract abnormalities
- Infertility and poor pregnancy outcomes
- Early menopause
Notably absent from this list is any mention of hepatotoxicity or liver enzyme abnormalities.
Context from Other Cases
One case report 3 mentions a patient with "in utero exposure to diethylstilbestrol" who later developed acute liver injury, but this was clearly attributed to tyrosine kinase inhibitor (pazopanib) therapy for angiosarcoma—not to the historical DES exposure. The DES exposure was simply part of the patient's past medical history and was not implicated in the liver injury.
Clinical Implications
- DES is not hepatotoxic: Unlike many hormonal agents and synthetic steroids that can cause liver enzyme elevation, DES does not appear to have this effect
- If ALT is elevated in a patient with DES history: Look for alternative causes (alcohol, viral hepatitis, fatty liver disease, other medications, etc.)
- Historical exposure only: Since DES was discontinued in the 1970s-1980s, any current patients would have been exposed decades ago, making it even less plausible as a cause of current liver enzyme abnormalities
Common Pitfall to Avoid
Do not attribute liver enzyme elevations to DES simply because it is a synthetic estrogen. While some hormonal therapies (particularly oral contraceptives and anabolic steroids) can cause hepatotoxicity 4, this is not a class effect of all estrogenic compounds. Each agent must be evaluated based on its specific pharmacologic profile and documented adverse effects.